Braftovi

Selected form

Encorafenib

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Braftovi

What is Braftovi? (Encorafenib Identity and Classification)

Property	Description
Active ingredient	Encorafenib
Form	Hard capsule (for oral use)
Pharmacological class	Kinase Inhibitor / Antineoplastic Agent
Primary action type	Targeted Therapy (BRAF inhibitor)
Origin	Synthetic, small molecule

Defining Encorafenib: A Targeted Antineoplastic Agent

Braftovi is the trade name for the synthetic, prescription-only medicine encorafenib, which is primarily classified as an antineoplastic agent. This classification places it within the therapeutic landscape of targeted therapy, specifically designed to counteract the growth of malignant cells by selective action.

Encorafenib is presented as a single-ingredient product delivered in a hard capsule for oral use. This small molecule inhibitor is distinct from traditional, non-selective chemotherapies as its uniqueness lies in its structure as an ATP-competitive RAF kinase inhibitor, which grants it a high biochemical affinity and specificity for its intended molecular target.

Classification as a Selective Kinase Inhibitor

Encorafenib functions as a selective kinase inhibitor, belonging to the subgroup of BRAF inhibitors. Kinases are regulatory enzymes, and encorafenib works by blocking the activity of the abnormal BRAF protein that is activated by genetic mutations. This inhibition disrupts the uncontrolled internal signaling of the MAP-kinase pathway (RAS/RAF/MEK/ERK) that drives certain forms of cellular proliferation.

This action is clinically recognized for its role in inhibiting key enzymes, confirming the medicine's function as a potent signal transduction inhibitor. Furthermore, pharmacological studies suggest encorafenib shows a distinct profile compared to other BRAF inhibitors in its sustained inhibition of the pathway.

General Therapeutic Purpose of BRAF Inhibition

The main therapeutic purpose of encorafenib is to exert molecular control over the advancement of malignant conditions driven by specific genetic changes, notably the BRAF V600E mutation. By stopping the continuous growth signals fueled by the mutated protein, the medicine helps to halt abnormal proliferation.

This targeted signaling blockade provides the primary benefit of directly interrupting the molecular cause of the disease. While Braftovi is a single entity, it is commonly utilized in therapeutic regimens alongside a MEK inhibitor, such as binimetinib, to achieve a more comprehensive molecular barrier.

Regulatory References

What side effects are possible with Braftovi?

Possible Side Effects and Safety Information

Regulatory documents classify the potential risks of Braftovi (encorafenib) according to frequency and the body system affected. This classification allows for a structured understanding of the medicine’s official safety profile, distinguishing between commonly observed effects and serious, clinically significant adverse reactions.

Frequency-Classified Adverse Reactions

The most frequently observed effects are classified as Very Common (occurring in 1/10 patients) and typically involve the gastrointestinal, musculoskeletal, and dermatological systems. Examples of very common reactions include fatigue, diarrhea, nausea, arthralgia (joint pain), musculoskeletal pain, and skin changes such as rash and Palmar-plantar erythrodysesthesia syndrome (PPES). Effects classified as Common (occurring in 1/100 to < 1/10 patients) include QT Prolongation and certain eye disorders like uveitis.

Serious Adverse Reactions and Safety Considerations

The official labeling documents highlight several potential serious adverse reactions. These include the development of New Primary Malignancies (such as cutaneous squamous cell carcinoma), Cardiomyopathy (Left Ventricular Dysfunction, LVD), Hemorrhage, and Hepatotoxicity. The medicine is associated with risks of Embryo-Fetal Toxicity and, according to regulatory statements, may cause infertility in males.

Safety notes also specify that certain events, such as specific ocular toxicities, have a documented median time to onset early in treatment. Additionally, patients with existing hepatic impairment are identified as a population where drug exposure may be increased, necessitating specific regulatory attention.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Braftovi

Overdose Scope

Documented overdose presentations: Overexposure is expected to cause an exaggeration of known severe toxicities, including dose-dependent QTc interval prolongation (cardiac risk), hepatotoxicity, and major hemorrhagic events as described in product labeling. Chronic overdose may present with milder symptoms such as grade 1 nausea, vomiting, and muscle pain, alongside slightly abnormal laboratory findings.

Physiological systems affected (as stated in label): Cardiovascular System (QT prolongation, cardiomyopathy), Hepatobiliary System (liver damage), and Vascular System (bleeding).

Dose-related or exposure-related factors (if applicable): Since encorafenib is approximately 86% bound to plasma proteins, regulatory documents note that hemodialysis is likely to be ineffective for drug removal in the event of overexposure.

Population-specific overdose notes (if applicable): Patients with hepatic impairment may be at increased risk of toxicity due to potential slower clearance and increased plasma exposure.

Emergency-response statements (as written in official documents): The official labeling states that no specific treatment recommendations or antidote are known for an overdose. Management must consist of symptomatic and supportive treatment with intensive physiological monitoring.

When immediate medical help is required (label-derived phrasing only): Immediate medical attention must be sought for severe manifestations, such as collapse, seizure, trouble breathing, or symptoms indicative of major toxicity like severe bleeding or signs of cardiac dysfunction.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents): Defined by the resulting severity of known Grade 3 or Grade 4 toxicities, particularly severe hemorrhage or QTc prolongation ge 500 ms.

Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information, EMA Summary of Product Characteristics (SmPC).

Overdose-context constraints (as defined in official documents): Management is constrained to general supportive measures and intensive monitoring of QTc interval, liver function, and electrolytes.

Resulting Overdose Structure

Official overdose statements:

No specific antidote is known for encorafenib overexposure.
Management requires symptomatic and supportive treatment under intensive monitoring.
Hemodialysis is likely to be ineffective due to high plasma protein binding.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile by documenting the exaggeration of severe toxicities, such as dose-dependent QTc prolongation and major hemorrhage, which necessitates the immediate seeking of medical attention. Given that no specific antidote is available, the mandated response involves providing symptomatic and supportive treatment alongside continuous observation and physiological monitoring (e.g., ECG, liver function) until the patient is stable. This approach is standard for managing overexposure to highly protein-bound agents.

Therapeutic Uses of Braftovi

What Braftovi Treats: Main Uses and Benefits

The therapeutic role of Braftovi (encorafenib) is centered on providing targeted systemic support to manage specific advanced, unresectable, or metastatic cancers in adults. Its use is relevant in conditions where tumors are confirmed to possess the BRAF V600E or V600K mutation.

Key Therapeutic Contexts

This medicine is commonly used to treat melanoma (a severe form of skin cancer) that has spread or cannot be removed surgically, as well as metastatic colorectal cancer (mCRC) and metastatic non-small cell lung cancer (mNSCLC). The treatment is applied across therapeutic domains where additional symptomatic support is needed to address conditions presenting with significant symptomatic burden.

The medicine is commonly used to help with managing the progression of the condition and maintaining stability. The use of this medicine supports general well-being during symptomatic phases. It may assist in easing severe systemic and localized symptoms associated with an active, advancing tumor, such as persistent fatigue and cancer-related pain. This support provides supportive relief that assists with maintaining functional stability, which helps patients cope more steadily with difficult episodes. In clinical scenarios, it is often used in combination with other anti-cancer agents where temporary assistance in symptom stabilization is important.

Quick Fact: Relief for Symptoms of Increased Physiological Strain

Regulatory References

European Medicines Agency (EMA) therapeutic overview

Eligibility and Restrictions for Use

Braftovi (encorafenib) eligibility is strictly defined by regulatory guidelines based on genetic status, age, and physiological function. The medicine is approved only for adult patients whose tumors have been confirmed to possess a BRAF V600E or V600K mutation. It is explicitly not indicated for patients whose tumors are BRAF wild-type (non-mutated) in the approved cancer types.

Use in children is not permitted, as safety and effectiveness in pediatric patients have not been established by regulators. Geriatric patients do not require a dose adjustment based on age alone. Regarding organ function, a recommended dose has not been established for patients with severe renal impairment or moderate-to-severe hepatic impairment (Child-Pugh B or C).

Braftovi is classified as having Embryo-Fetal Toxicity. Therefore, pregnant women must not use the medicine, and females of reproductive potential must use an effective non-hormonal method of contraception. Women are also advised not to breastfeed during treatment and for two weeks following the final dose.

What should I know about interactions with other medicines?

Braftovi Interactions with other medicines and products

Braftovi (encorafenib) is subject to several clinically significant drug interactions, primarily due to its effects on drug-metabolizing CYP450 enzymes, specifically CYP3A4, and its potential to affect cardiac rhythm.

Interacting Product Category	Effect on Braftovi or Co-administered Drug
Strong or Moderate CYP3A4 Inhibitors (e.g., grapefruit juice)	Avoid coadministration; these increase Braftovi concentration, potentially increasing side effects. If unavoidable, a Braftovi dose reduction is required and must be resumed to the original dose after the inhibitor is discontinued.
Strong CYP3A4 Inducers	Avoid coadministration; these decrease Braftovi concentration, potentially reducing its effectiveness.
Sensitive CYP3A4 Substrates (e.g., hormonal contraceptives)	Avoid coadministration; Braftovi is a strong CYP3A4 inducer, which can significantly decrease the concentrations and efficacy of these substrates. Females of reproductive potential must use effective non-hormonal contraception.
Drugs that prolong the QT/QTc interval	Avoid coadministration; Braftovi is associated with dose-dependent QTc interval prolongation, which increases the risk of serious heart rhythm abnormalities.
OATP1B1, OATP1B3, or BCRP Substrates	Braftovi can increase the concentrations of these substrate medicines. Dose reductions of the co-administered substrate may be required.

The interaction profile of Braftovi is defined by its role as a strong inducer of CYP3A4 at steady-state and its own dependence on CYP3A4 for metabolism. Strict adherence to avoidance or dose modification rules for these categories is necessary, as outlined in regulatory documents, to manage risks associated with both reduced Braftovi efficacy and increased toxicity of co-administered medicines.

Mechanism of Action

How Braftovi Works: Mechanism of Action

Braftovi (encorafenib) functions as a highly specific, targeted inhibitor to block the uncontrolled signaling driven by the BRAF V600 mutation. Its mechanism is defined by three interconnected steps at the cellular level.

Selective Blockade of the Mutated BRAF Enzyme

The mechanism begins with the selective, ATP-competitive inhibition of the mutated BRAF V600 protein. Encorafenib binds tightly to the enzyme's active site, preventing it from transferring the necessary energy (ATP) to its downstream partners. This targeted action cuts off the constitutive kinase signaling originating from the mutated enzyme, providing the primary molecular basis for the resulting cellular changes.

Profound Suppression of the MAPK Signaling Cascade

The inhibition of BRAF initiates a cascade that achieves a profound suppression of the entire MAPK (RAS/RAF/MEK/ERK) signaling pathway. This reduction in signaling prevents the subsequent activation of MEK and ERK proteins. This cascade ultimately leads to two key physiological consequences in the target cells: G1 cell cycle arrest and the induction of cellular senescence or programmed cell death (apoptosis).

️ Synergistic Strategy Against Adaptive Resistance

To preempt cellular mechanisms of bypass, encorafenib is used in a synergistic strategy alongside other agents. Combining it with a MEK inhibitor (e.g., binimetinib) ensures a more complete blockade of the pathway, while adding an EGFR antagonist (e.g., cetuximab) counteracts an adaptive feedback loop where the cell attempts to reactivate the pathway via the EGFR receptor. This comprehensive approach maintains suppression over the dysregulated signaling.

Dosage and Administration Information

How to Use Braftovi: Official Dosing and Administration

Braftovi (encorafenib) is a targeted medicine for oral administration only. Its use is strictly defined by guidelines and is contingent upon confirmation of a BRAF V600 mutation in the cancer. The medicine is delivered in hard capsules, available in 50 mg and 75 mg strengths.

Standard Dosing Regimens (Adults)

The medicine is always used in a combination regimen. The starting dose and specific combination partner depend on the condition being treated, as outlined in official prescribing information:

Indication	Braftovi Dose	Frequency	Combination Partner
Unresectable or Metastatic Melanoma	450 mg	Once Daily	Binimetinib
Metastatic Colorectal Cancer (mCRC)	300 mg	Once Daily	Cetuximab

Practical Administration Guidelines

Treatment is intended to be continuous until the disease progresses or the patient develops unacceptable toxicity.

Food Intake: Braftovi may be taken with or without food.
Missed Dose: If a dose is missed, it should not be taken if the next scheduled dose is due within 12 hours. Patients should resume dosing with the next scheduled dose.
Dose Contingency: If the combination partner (Binimetinib) is temporarily interrupted, the Braftovi dose must be reduced to 300 mg until the partner medicine is resumed.

Population-Specific Use

No dose adjustment is necessary for patients with mild-to-moderate renal impairment. However, Braftovi is not recommended for patients with moderate to severe hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Braftovi

Evidence Overview for Unresectable or Metastatic Melanoma

The primary research for Braftovi (encorafenib) in advanced melanoma is derived from large, multi-center Randomized Controlled Trials (RCTs). These studies included adult participants with the BRAF V600E or V600K mutation, covering groups who were either treatment-naïve or previously treated. The research was structured to compare the Braftovi combination regimen to a prior BRAF inhibitor used alone.

Studies examined critical outcomes, including the time lived without the disease progressing (Progression-Free Survival, PFS) and the total duration of life (Overall Survival, OS). Findings from these trials describe the outcomes measured for survival and tumor response in the Braftovi combination group versus the control group.

Evidence Overview for Metastatic Colorectal Cancer (mCRC)

For BRAF V600E-mutant metastatic colorectal cancer, the evidence base includes pivotal Randomized Controlled Trials (RCTs) for previously treated adult participants. More recent research has explored the use of the Braftovi combination in previously untreated (first-line) participants. Studies monitored outcomes related to functional imbalance, specifically the Overall Survival (OS) and Progression-Free Survival (PFS).

What remains uncertain is the long-term clinical outcome for the previously untreated patient population, as the final survival data is contingent on the completion of the ongoing confirmatory Phase 3 study.

Evidence Overview for Advanced Non-Small Cell Lung Cancer (mNSCLC)

The research landscape for advanced BRAF V600E-mutant non-small cell lung cancer is primarily built upon a single-arm, non-comparative Phase 2 Multicenter Trial. The primary focus was to measure the Objective Response Rate (ORR), with secondary measurements including the Duration of Response (DOR) and Overall Survival (OS). Long-term follow-up analyses describe patterns related to OS in these patient groups.

A key limitation is that the pivotal research was a single-arm study, which means comparative evidence against other standard systemic therapies is lacking within the trial structure.

Long-Term Research and Study Gaps

Clinical research includes dedicated efforts to track outcomes over defined time intervals. For melanoma, the pivotal Phase 3 trial has published long-term follow-up analyses extending up to seven years. However, long-term effects beyond the observation period are not fully established, and continued data collection remains important. Data for certain groups, such as those with severe pre-existing cardiovascular conditions, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Braftovi (FAQ)

Q: Are there any specific over-the-counter (OTC) pain relievers that are known to interact with Braftovi?

A: Regulatory documents state that Braftovi (encorafenib) is known to interact with certain drugs that affect the CYP3A4 enzyme. This enzyme helps the body process many substances. While specific over-the-counter (OTC) pain relievers are not individually named on the drug label, those that fall into these enzyme categories may change the concentration of Braftovi in the body. Patients are generally advised to discuss all co-administered medicines, including OTC pain relievers, with their healthcare team to manage potential interactions.

Q: Is it a common practice to interrupt or reduce the dose of Braftovi due to side effects?

A: Yes, official prescribing information includes specific instructions for dose modification (reduction or interruption) to manage certain adverse reactions. These instructions are detailed in regulatory guides to help manage common side effects like skin toxicities or heart rhythm changes. The purpose of these modifications is to manage side effects, which may help maintain patient tolerability and treatment continuity.

Q: Does taking Braftovi make a person more sensitive to the sun (photosensitivity)?

A: Studies and official information indicate that photosensitivity reactions (increased sensitivity to the sun) have been reported in patients taking Braftovi in combination with binimetinib. This type of reaction is considered uncommon, meaning it occurs in less than 1 in 100 patients. Patients are typically advised to speak with their healthcare provider about strategies for managing sun exposure and skin protection.

Q: How does Braftovi affect a person's blood counts, such as anemia?

A: Official product information notes that Braftovi is associated with changes in blood counts. Anemia, which is a decrease in red blood cells or hemoglobin, is a commonly reported laboratory abnormality, especially when used in combination regimens. Monitoring for these changes typically involves regular blood tests during the course of treatment, as outlined in prescribing information.

Q: Are there any major differences in the side effects when Braftovi is used for melanoma versus colorectal cancer?

A: Yes, the frequency of certain side effects can vary depending on the combination regimen and the condition being treated. Regulatory safety tables indicate that some events, such as dermatitis acneiform (a rash) or peripheral neuropathy (nerve damage), may be observed more frequently when Braftovi is used in certain combination therapies, such as the regimen for colorectal cancer.

Q: Does Braftovi cause hair loss (alopecia)?

A: Official regulatory documents list alopecia (hair loss) as a commonly reported side effect in patients using Braftovi. When experiencing hair loss while on this medicine, patients are generally encouraged to consult their physician regarding the degree of change and potential management strategies.

Q: Is it necessary to have regular eye exams while taking Braftovi?

A: Yes, regulatory documents recommend that patients be monitored for any visual symptoms at each visit due to the risk of ocular (eye) toxicities like uveitis. Official guidance states that an ophthalmological evaluation (eye exam) may be performed if a patient experiences new or worsening visual disturbances.

Q: What specific laboratory tests are used to monitor a person's health while taking Braftovi?

A: Patients on Braftovi require regular monitoring using specific laboratory tests to check for potential adverse effects. These tests typically include liver laboratory tests (such as AST/ALT) taken before treatment and regularly thereafter. Additionally, heart function, specifically the Left Ventricular Ejection Fraction (LVEF), is assessed before starting treatment and periodically during the course of therapy.

Q: Why is it important for melanoma to be 'unresectable' or 'metastatic' for Braftovi use?

A: The official indication for Braftovi in melanoma is specifically for tumors that are unresectable (meaning they cannot be removed completely by surgery) or metastatic (meaning the cancer has spread from the original site). This reflects the advanced stage of the disease where the medicine has been studied and demonstrated efficacy in clinical trials, according to regulatory approvals.

Q: Can Braftovi cause nerve damage, such as tingling in the hands or feet (peripheral neuropathy)?

A: Yes, peripheral neuropathy has been reported as a commonly observed side effect in patients taking Braftovi. This condition involves damage to the nerves that can lead to symptoms like numbness, tingling, or burning in the hands or feet. This side effect is specifically noted in the official regulatory product information.

Q: How does Braftovi affect blood sugar levels (hyperglycemia)?

A: Clinical trial data, reflected in regulatory documents, lists increased glucose (blood sugar) levels as a commonly reported laboratory abnormality. This finding is specifically noted when Braftovi is used as part of certain combination regimens. Monitoring of blood sugar levels may be recommended during treatment, as directed by the treating physician.

Q: Is swelling of the hands or feet (edema) a common occurrence with Braftovi?

A: Yes, official safety information indicates that peripheral edema (swelling of the hands, feet, or other extremities) is a common adverse reaction. It has been reported in more than 1 in 10 patients in clinical trials. If this is experienced, patients are generally advised to discuss it with the treating physician.

Q: Does Braftovi have the potential to interact with common antibiotics?

A: Braftovi’s concentration in the body can be significantly affected by strong or moderate CYP3A4 inhibitors. Because some common antibiotics belong to this class of inhibitors, there is a potential for interaction. Regulatory documents note that if Braftovi is co-administered with a drug known to inhibit CYP3A4, the treatment plan may require adjustment or additional monitoring.

How should Braftovi be stored and disposed of?

Braftovi (encorafenib) capsules must be stored according to regulatory requirements to preserve product quality.

Item	Labeled Regulatory Requirement
Storage Temperature	Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C
Protection/Handling	Store in the original bottle; keep tightly closed and protected from moisture; do not remove the desiccant packet
Child Safety	Keep out of the sight and reach of children
Disposal Instructions	Unused medicine must be discarded in accordance with local requirements and must not be disposed of in household trash or wastewater